Genomics drug resistance prediction

There are emerging genomic predictive markers for trastuzumab resistance (e.g., high IGF-IR and loss of PTEN (32,33), that do not appear to preclude clinical response to lapatinib (34). The ability to distinguish patients who benefit from one drug vs. another, based on PGX markers, is of obvious clinical interest. These examples illustrate that... 

In an effort to find a way to predict chemotherapy sensitivity, Staunton et al. [61] conducted microarray assays using 232 cytotoxic chemotherapeutic drugs in a panel of 60 human cancer cell lines (the NCI-60). Expression profile-based classifiers of sensitivity or resistance to these compounds were generated and then evaluated on independent sets of data. About one-fourth of the elassifiers performed accurately, suggesting that at least for a subset of compounds, genomic approaches to chemosensitivity prediction are feasible. These signatures have recently been further validated to be able to accurately predict clinical response in individuals treated with these drugs [62]. 

---